Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
出版年份 2013 全文链接
标题
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
作者
关键词
-
出版物
Annals of the New York Academy of Sciences
Volume 1291, Issue 1, Pages 14-32
出版商
Wiley
发表日期
2013-05-10
DOI
10.1111/nyas.12122
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
- (2014) Terence O'Reilly et al. Translational Oncology
- Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
- (2013) John J Bissler et al. LANCET
- Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma
- (2013) D. A. Krueger et al. NEUROLOGY
- Safety and efficacy of everolimus- versus sirolimus-eluting stents: A systematic review and meta-analysis of 11 randomized trials
- (2012) Kyung Woo Park et al. AMERICAN HEART JOURNAL
- Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) K. Oberg et al. ANNALS OF ONCOLOGY
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) B. Escudier et al. ANNALS OF ONCOLOGY
- Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
- (2012) S Bracarda et al. BRITISH JOURNAL OF CANCER
- Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors
- (2012) Yevgeniy Balagula et al. CANCER
- Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial
- (2012) Camillo Porta et al. EUROPEAN UROLOGY
- Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma
- (2012) P. Korhonen et al. Journal of Biopharmaceutical Statistics
- Everolimus for Tumor Recurrence After Surgical Resection for Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex
- (2012) David Neal Franz et al. JOURNAL OF CHILD NEUROLOGY
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
- (2012) David Neal Franz et al. LANCET
- Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer
- (2012) Chad M. Barnett PHARMACOTHERAPY
- Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
- (2011) Camillo Porta et al. EUROPEAN JOURNAL OF CANCER
- Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
- (2011) E. Calvo et al. EUROPEAN JOURNAL OF CANCER
- Research and innovation in the development of everolimus for oncology
- (2011) David Lebwohl et al. Expert Opinion on Drug Discovery
- Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis
- (2011) David Neal Franz Expert Review of Anticancer Therapy
- Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
- (2011) Phuong K. Morrow et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus-Eluting Versus Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
- (2011) Kyung Woo Park et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents
- (2011) Gregg W. Stone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice
- (2011) Pieter C. Smits et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
- (2010) Dorothy A. White et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) B. Escudier et al. ANNALS OF ONCOLOGY
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) F. Cardoso et al. ANNALS OF ONCOLOGY
- Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer
- (2010) Vicky S. Sabine et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
- (2010) Guy Jerusalem et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- New inhibitors of the mammalian target of rapamycin signaling pathway for cancer
- (2010) Sébastien Albert et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
- (2010) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial
- (2010) Elvin Kedhi et al. LANCET
- Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease
- (2010) Gregg W. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
- (2009) Robert J. Amato et al. CANCER
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- (2009) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
- (2009) RuiRong Yuan et al. Journal of Hematology & Oncology
- Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis
- (2009) Kristen Pollizzi et al. Molecular Cancer
- Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
- (2008) Chiaki Tanaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function
- (2008) L. Meikle et al. JOURNAL OF NEUROSCIENCE
- Tuberous sclerosis
- (2008) Paolo Curatolo et al. LANCET
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started